1,2,3,4-tetrahydroquinoline-1-sulfonyl chloride | 816449-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,2,3,4-tetrahydroquinoline-1-sulfonyl chloride
• 英文别名: (1,2,3,4-tetrahydroquinolinyl)sulfamoyl chloride；3,4-dihydro-1(2H)-quinolinesulfonyl chloride；1(2H)-Quinolinesulfonyl chloride, 3,4-dihydro-；3,4-dihydro-2H-quinoline-1-sulfonyl chloride
• CAS: 816449-11-3
• 化学式: C₉H₁₀ClNO₂S
• 分子量: 231.703
• InChiKey: KZOLMXOHXUCZTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2,3,4-tetrahydroquinoline-1-sulfonyl chloride 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 ethyl 2-[3,4-dihydro-2H-quinolin-1-ylsulfonyl-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]acetate
  参考文献：
  名称：

  Efficient synthesis of arylsulfamides by reaction of amines with arylsulfamoyl imidazolium triflate

  摘要：

  Aryisulfamoyl imidazolium triflates, readily prepared from the corresponding chlorides, react with amines under neutral conditions to form arylsulfamides in high yields. This methodology, which contrasts with the slow and inefficient reactions of amines with arylsulfamoyl chlorides, is applied to the synthesis of arylsulfamide 3a, a bioisotere of muraglitazar. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.08.092
• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 在 氯磺酸 、 五氯化磷 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 19.25h， 生成 1,2,3,4-tetrahydroquinoline-1-sulfonyl chloride
  参考文献：
  名称：

  [EN] GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
  [FR] INHIBITEURS DE TRANSPORTEURS DE GLYT1 ET LEURS UTILISATIONS DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES

  摘要：

  提供化学式(I)、盐、溶剂化合物和其生理功能衍生物：化学式(I)中R1和R2独立选择自氢、可选择取代的C1-6烷基、可选择取代的C3-6环烷基、可选择取代的芳基、可选择取代的芳基C1-4烷基和可选择取代的芳基C3-6环烷基，其中R1和R2不能同时为氢，或者R1和R2与它们连接的氮原子一起形成一个可选择取代的4、5、6或7成员饱和环，其中一个或多个碳原子可选择由N、O和S中独立选择的杂原子替代；R3是一个化学式(a)的可选择取代基团：其中m和n独立取0、1、2或3，m+n为2、3或4；每个Z独立为-CH2-、-NH-、-O-或-S-；每个Y独立为CH或N；R4和R5独立选择自氢、可选择取代的C1-C6烷基、可选择取代的C3-C6环烷基、可选择取代的芳基和可选择取代的芳基C1-C4烷基；R6、R7、R8和R9独立选择自氢、可选择取代的C1-C6烷基和可选择取代的芳基C1-C4烷基，或者R6和R7一起形成一个可选择取代的C3-C6环烷基基团，或者R8和R9一起形成一个可选择取代的C3-C6环烷基基团。还公开了制备方法和在医学上用于治疗由GlyT1介导的疾病，例如精神分裂症的化合物的用途。

  公开号：

  WO2004113301A1

文献信息

• [EN] SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME<br/>[FR] DERIVES DE SULFAMIDE ET COMPOSITION PHARMACEUTIQUE SERVANT A REGULER POSITIVEMENT LE METABOLISME DES LIPIDES ET CONTENANT CES DERIVES
  申请人：CRYSTALGENOMICS INC

  公开号：WO2006006832A1

  公开（公告）日：2006-01-19

  The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.

  本发明涉及一种新型磺胺酰胺衍生物，其药用可接受的盐以及一种含有其作为活性成分的用于上调脂质代谢的制药组合物。
• [EN] GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS<br/>[FR] INHIBITEURS DE TRANSPORTEURS DE GLYT1 ET LEURS UTILISATIONS DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004113301A1

  公开（公告）日：2004-12-29

  Compounds of formula (I), salts, solvates and physiologically functional derivatives thereof are provided: formula (I) wherein R1 and R2 is independently selected from hydrogen, optionally substituted C1-6alkyl, optionally substituted C3-6cycloalkyl, optionally substituted aryl, optionally substituted arylC1-4alkyl and optionally substituted arylC3-6cycloalkyl, wherein R1 and R2 are not both hydrogen, or R1 and R2, together with the nitrogen atom to which they are attached, are linked to form an optionally substituted 4-, 5-, 6- or 7-membered saturated ring, wherein one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S; R3 is an optionally substituted group of formula (a): wherein m and n are independently 0, 1, 2 or 3 and m+n is 2, 3 or 4; each Z is independently -CH2-, -NH-, -O- or -S-; and each Y is independently CH or N; R4 and R5 are independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted aryl and optionally substituted arylC1-C4 alkyl; and R6, R7, R8 and R9 are independently selected from hydrogen, optionally substituted C1-C6 alkyl and optionally substituted arylC1-C4 alkyl, or R6 and R7 together form an optionally substituted C3-C6 cycloalkyl group, or R8 and R9 together form an optionally substituted C3-C6 cycloalkyl group. Methods of preparation and uses of the compounds in medicine for the treatment of a disorder mediated by GlyT1, for example schizophrenia, are also disclosed.

  提供化学式(I)、盐、溶剂化合物和其生理功能衍生物：化学式(I)中R1和R2独立选择自氢、可选择取代的C1-6烷基、可选择取代的C3-6环烷基、可选择取代的芳基、可选择取代的芳基C1-4烷基和可选择取代的芳基C3-6环烷基，其中R1和R2不能同时为氢，或者R1和R2与它们连接的氮原子一起形成一个可选择取代的4、5、6或7成员饱和环，其中一个或多个碳原子可选择由N、O和S中独立选择的杂原子替代；R3是一个化学式(a)的可选择取代基团：其中m和n独立取0、1、2或3，m+n为2、3或4；每个Z独立为-CH2-、-NH-、-O-或-S-；每个Y独立为CH或N；R4和R5独立选择自氢、可选择取代的C1-C6烷基、可选择取代的C3-C6环烷基、可选择取代的芳基和可选择取代的芳基C1-C4烷基；R6、R7、R8和R9独立选择自氢、可选择取代的C1-C6烷基和可选择取代的芳基C1-C4烷基，或者R6和R7一起形成一个可选择取代的C3-C6环烷基基团，或者R8和R9一起形成一个可选择取代的C3-C6环烷基基团。还公开了制备方法和在医学上用于治疗由GlyT1介导的疾病，例如精神分裂症的化合物的用途。
• Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban
  申请人：Euticals S.P.A.

  公开号：US20160122303A1

  公开（公告）日：2016-05-05

  The present invention relates to the biocatalyzed synthesis of enantiomerically pure (3R) and (3S)-methyl-1,2,3,4-tetrahydroquinoline. Said enantiomerically pure compounds are useful as chiral synthons in organic synthesis and, in particular, for the preparation of diastereomerically pure (21R) and (21S)-agratroban and its analogues. New compounds used as intermediates in the process of the invention are also disclosed.

  本发明涉及生物催化合成对映纯的(3R)和(3S)-甲基-1,2,3,4-四氢喹啉。所述对映纯化合物在有机合成中作为手性合成物起到有用作用，特别是用于制备对映异构体纯的(21R)和(21S)-阿格曲班及其类似物。本发明还公开了作为中间体在该过程中使用的新化合物。
• Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same
  申请人：Cho Myung Joong

  公开号：US20070254882A1

  公开（公告）日：2007-11-01

  The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.

  本发明涉及一种新型磺酰胺衍生物、其药学上可接受的盐以及包含其作为活性成分的上调脂质代谢的药物组合物。
• Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban
  申请人：Euticals S.P.A.

  公开号：EP2824187A1

  公开（公告）日：2015-01-14

  The present invention relates to the biocatalyzed synthesis of enantiomerically pure (3R) and (3S)-methyl-1,2,3,4-tetrahydroquinoline. Said enantiomerically pure compounds are useful as chiral synthons in organic synthesis and, in particular, for the preparation of diastereomerically pure (21 R) and (21 S)-agratroban and its analogues. New compounds used as intermediates in the process of the invention are also disclosed.

  本发明涉及生物催化合成对映体纯的(3R)和(3S)-甲基-1,2,3,4-四氢喹啉。上述对映体纯化合物可用作有机合成中的手性合成子，特别是用于制备非对映纯的（21 R）和（21 S）-阿曲洛班及其类似物。此外，还公开了在本发明工艺中用作中间体的新化合物。